Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Latest News on CPIX

Mar 19, 2025, 4:05 PM EDT - 15 days ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 4 weeks ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 4 weeks ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 5 weeks ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 6 weeks ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 2 months ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 2 months ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 4 months ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 4 months ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 5 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 5 months ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 5 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 5 months ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 8 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 8 months ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 11 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 11 months ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 1 year ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 1 year ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Jun 26, 2023, 9:00 AM EDT - 1 year ago

NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS

May 23, 2023, 9:00 AM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

May 15, 2023, 9:00 AM EDT - 2 years ago

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

May 13, 2023, 5:45 PM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

May 2, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Mar 7, 2023, 10:47 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 4:23 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022

Feb 28, 2023, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Nov 12, 2022, 8:53 PM EST - 2 years ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q3 2022 Earnings Call Transcript

Nov 8, 2022, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports 41% Revenue Growth

Nov 1, 2022, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

Nov 1, 2022, 9:20 AM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST

Aug 13, 2022, 2:07 PM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2022 Results - Earnings Call Transcript

Aug 9, 2022, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports 14% Revenue Growth

Aug 8, 2022, 9:25 AM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021

Aug 2, 2022, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

Jul 19, 2022, 9:25 AM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

May 14, 2022, 5:42 PM EDT - 3 years ago

Market Cap	60.90M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.68

Volume	34,452
Avg Vol	1,809,690
Day's Range	N/A - N/A
Shares Out	13.97M
Stochastic %K	57%
Beta	-0.24
Analysts	Strong Buy
Price Target	$8.50